FDA urges QbD approach for transdermal patches
This article was originally published in The Gold Sheet
Executive SummaryFDA asked manufacturers in an Aug. 3 draft guidance document to use quality-by-design approaches to minimize the amount of residual drug left in transdermal patches. The guidance notes that currently marketed transdermal patches may retain 10 to 95 percent of the initial total amount of the drug after the intended use, raising a potential safety issue for patients and their family members
You may also be interested in...
Biodegradable plastic alternatives for use in cosmetic products were left unaddressed, and thus arguably unusable, under the US Microbead-Free Waters Act enacted in late 2015. European industry stakeholders now face the prospect of a far more extensive microplastic ban, and the viability of bioplastics to replace conventional, petroleum-based microplastics is an area in need of work.
Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.